CastleArk Management »

Protagonist Therapeutics shares owned by CastleArk Management

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by CastleArk Management from 13F filings

Historical chart of CastleArk Management investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by CastleArk Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by CastleArk Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $6.2M 51k 122.58

More positions owned by CastleArk Management

NVIDIA Corporation (NVDA)
Alphabet Cap Stk Cl A (GOOGL)
Apple (AAPL)
Lam Research Corp Com New (LRCX)
Microsoft Corporation (MSFT)
Eli Lilly & Co. (LLY)
Broadcom (AVGO)
Spdr Series Trust St Inter Bd Etf (SPIB)
Visa Com Cl A (V)
Arista Networks Com Shs (ANET)
Ishares Tr Us Treas Bd Etf (GOVT)
Vanguard Scottsdale Fds Mtg-bkd Secs Etf (VMBS)
Advanced Micro Devices (AMD)
Gilead Sciences (GILD)
Amazon (AMZN)

View all positions for CastleArk Management

Top funds holding Protagonist Therapeutics

BlackRock
Farallon Capital Management
Rtw Investments
Vanguard Portfolio Management
Wellington Management Company
UBS Group
State Street Corporation
Henderson Group
Vanguard Capital Management
Johnson & Johnson
Invesco
Jupiter Topco
Geode Capital Management
T. Rowe Price Associates
Woodline Partners

View all funds holding Protagonist Therapeutics